VERSIONS OF RECOMBINANT AAV AND USE THEREOF Russian patent published in 2020 - IPC A01K67/27 A61K35/00 A61K48/00 C07K14/05 C12N15/113 C12N15/85 C12N15/86 C12N7/00 

FIELD: biotechnology; genetic engineering.

SUBSTANCE: recovered AAV capsid protein contains a sequence selected from the group consisting of: SEQ ID NO: from 51 to 61. Recombinant expression vector contains a nucleic acid sequence coding the isolated capsid AAV protein. Composition for transgene delivery to the patient contains isolated capsid AAV protein and a pharmaceutically acceptable carrier. Recombinant AAV (rAAV) contains extracted capsid AAV protein. Composition for transgene delivery to a patient comprises recombinant rAAV and a pharmaceutically acceptable carrier. Method for delivering a transgene to a patient comprises administering rAAV to a patient, wherein rAAV contains at least one transgene and in which rAAV infects target tissue cells. Method for creating a somatic transgenic animal model involves administering recombinant rAAV to an animal other than a human, wherein rAAV contains at least one transgene and in which rAAV infects a cell of a target tissue of an animal other than a human. Kit for producing rAAV contains a container containing recombinant AAV having an isolated capsid AAV protein.

EFFECT: group of inventions provides improved properties of tissue tropism.

16 cl, 4 dwg, 5 tbl, 1 ex